1. Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis 
Christian Grommes, Anas Younes 
Cancer Cell 
Volume 31, Issue 6, Pages (June 2017)
DOI: /j.ccell
Copyright © Terms and Conditions

2. Figure 1 Therapeutic Targeting of BTK in PCNSL
(A) Activity of single-agent ibrutinib in PCNSL. (B) Ibrutinib inhibition of BTK in tumor cells induces favorable clinical responses, while inhibition of BTK in monocytes may lead to an increased incidence of invasive aspergillosis.
Cancer Cell  , DOI: ( /j.ccell )
Copyright © Terms and Conditions